Ghassan K. Abou-Alfa, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings showing improvement in progression-free survival among patients with an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib compared with a similar group that received placebo (Abstract LBA10).
Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses study findings from the first phase III trial to show PD-1 and CTLA-4 inhibition is effective in non–small cell lung cancer, with improved overall survival vs chemotherapy (Abstract LBA4).
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyond hormone receptor status in HER2-positive early breast cancer (Abstract 248P).
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses the efficacy of prostate radiotherapy plus androgen-deprivation therapy with or without docetaxel in patients with prostate cancer with only lymph node metastases or less than four bone metastases (Abstract 844O).
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre at the University of Melbourne, and Leisha A. Emens, MD, PhD, of UPMC Hillman Cancer Center, discuss overall survival in this phase II study of atezolizumab/trastuzumab emtansine (T-DM1) vs placebo/T-DM1 in previously treated HER2-positive advanced breast cancer (Abstract 305O).
Maha H.A. Hussain, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, discusses the phase III PROfound trial results on the efficacy of olaparib in men with metastatic castration-resistant prostate cancer whose tumors harbor alterations in DNA damage response genes and who had disease progression on prior hormone therapy (Abstract LBA12).
